Roots Analysis has done a detailed study on High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030, covering key aspects of the industry’s evolution and identifying
potential future growth opportunities.

Key Market Insights
• Presently, over 100 service providers across the globe have capabilities to handle high energy / hazardous chemistry conditions, offering contract and custom manufacturing services for pharmaceutical APIs
• The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of the companies have presence in Europe and Asia Pacific regions
• API manufacturing facilities of service providers are well equipped to handle / maintain a wide range of temperature and pressure conditions to carry out HEC reactions
• Industry stakeholders are actively expanding their existing capabilities through installation of advanced equipment at their manufacturing facilities, in order to maintain a competitive edge in the market
• Service Providers are offering a diverse portfolio of reactions for manufacturing of synthetic APIs; Hydrogenation and Grignard reactions are the most popular types of reactions offered by players
• Case In Point: Contract research service providers cater to the needs related to process development and small scale synthesis of APIs based on HEC / hazardous chemistry
• In the long-term, the projected opportunity is anticipated to be worth USD 29 billion by 2030; the opportunity is anticipated to be well distributed across companies of varying sizes, scale of operation and geographies

Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of High Energy Chemistry (HEC) / Hazardous Chemistry for Small Molecule API Manufacturing
3.3. Low Temperature / Cryogenic Chemistry
3.3.1. Reaction Conditions
3.3.2. Advantages
3.3.3. Affiliated Production Processes
3.3.4. Other Specific Requirements / Equipment
3.3.5. List of Reactions
3.4. High Temperature Chemistry
3.4.1. Reaction Conditions
3.4.2. Advantages
3.4.3. Affiliated Production Processes
3.4.4. Other Specific Requirements / Equipment
3.4.5. List of Reactions
3.5. High Pressure Chemistry
3.5.1. Reaction Conditions
3.5.2. Advantages
3.5.3. Affiliated Production Processes
3.5.4. Other Specific Requirements / Equipment
3.5.5. List of Reactions
3.6. Need for Outsourcing HEC / Hazardous Chemistry-Based API Manufacturing in the Pharmaceutical Industry
3.7. Shift Towards Continuous Flow Chemistry

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges
4.3 HEC / Hazardous Chemistry for Small Molecule Manufacturing

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. API Manufacturers with HEC Capability: Overall Market Landscape
5.2.1. Analysis by Type of Manufacturing Service
5.2.2. Analysis by Year of Establishment
5.2.3. Analysis by Company Size
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by General Pharmaceutical Manufacturing Portfolio
5.2.6.1. Analysis by Type of Product (API and FDF)
5.2.6.2. Analysis by HPAPI Manufacturing Capability
5.2.7. Analysis by Type of HEC Services Offered
5.2.7.1. Analysis by Temperature Conditions Handled
5.2.7.2. Analysis by Pressure Conditions Handled
5.2.8. Analysis by Availability of Continuous Flow Technology

6. REGIONAL CAPABILITY ASSESSMENT
6.1. Chapter Overview
6.2. List of Manufacturing Facilities having HEC Capabilities
6.2.1. Manufacturing Facilities in North America
6.2.1.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in North America
6.2.1.2. Analysis by Type of Reaction Conditions Handled
6.2.1.3. Analysis by Range of Reaction Conditions Handled
6.2.1.3.1. Analysis by Temperature Conditions Handled
6.2.1.3.2. Analysis by Pressure Conditions Handled
6.2.2. Manufacturing Facilities in Europe
6.2.2.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in Europe
6.2.2.2. Analysis by Type of Reaction Conditions Handled
6.2.2.3. Analysis by Range of Reaction Conditions Handled
6.2.2.3.1. Analysis by Temperature Conditions Handled
6.2.2.3.2. Analysis by Pressure Conditions Handled
6.2.3. Manufacturing Facilities in Asia Pacific
6.2.3.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in Asia Pacific
6.2.3.2. Analysis by Type of Reaction Conditions Handled
6.2.3.3. Analysis by Range of Reaction Conditions Handled
6.2.3.3.1. Analysis by Temperature Conditions Handled
6.2.3.3.2. Analysis by Pressure Conditions Handled
6.3. Regional Capability Assessment Summary

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters
7.3. Methodology
7.4. Competitiveness Analysis: Companies in North America
7.4.1. Companies in North America Offering HEC-based Contract Manufacturing
7.4.2. Companies in North America Offering HEC-based Custom Manufacturing
7.5. Competitiveness Analysis: Companies in Europe
7.5.1. Companies in Europe Offering HEC-based Contract Manufacturing
7.5.2. Companies in Europe Offering HEC-based Custom Manufacturing
7.6. Competitiveness Analysis: Companies in Asia Pacific
7.6.1. Companies in Asia Pacific Offering HEC-based Contract Manufacturing
7.6.2. Companies in Asia Pacific HEC-based Offering Custom Manufacturing
7.7. Spider Web Analysis

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AGC Chemicals
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Manufacturing Facility Details
8.2.4. HEC Specific Service Offerings
8.2.5. Recent Developments and Future Outlook
8.3. Beijing Mediking Biopharm
8.3.1 Company Overview
8.3.2 Manufacturing Facility Details
8.3.3 HEC Specific Service Offerings
8.3.4. Recent Developments and Future Outlook
8.4. Cambrex
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Manufacturing Facility Details
8.4.4. HEC Specific Service Offerings
8.4.5. Recent Developments and Future Outlook
8.5. Corden Pharma
8.5.1 Company Overview
8.5.2 Manufacturing Facility Details
8.5.3 HEC Specific Service Offerings
8.5.4 Recent Developments and Future Outlook
8.6. Evonik
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Manufacturing Facility Details
8.6.4. HEC Specific Service Offerings
8.6.5. Recent Developments and Future Outlook
8.7. Hovione
8.7.1. Company Overview
8.7.2. Manufacturing Facility Details
8.7.3. HEC Specific Service Offerings
8.7.4. Recent Developments and Future Outlook
8.8. Patheon
8.8.1. Company Overview
8.8.2. Manufacturing Facility Details
8.8.3. HEC Specific Service Offerings
8.8.4. Recent Developments and Future Outlook
8.9. PCI Synthesis
8.9.1. Company Overview
8.9.2. Manufacturing Facility Details
8.9.3. HEC Specific Service Offerings
8.9.4. Recent Developments and Future Outlook
8.10. Siegfried
8.10.1. Company Overview
8.10.2. Manufacturing Facility Details
8.10.3. HEC Specific Service Offerings
8.10.4. Financial Information
8.10.5. Recent Developments and Future Outlook

For more information, please click on the following link:
https://www.rootsanalysis.com/reports/high-energy-chemistry.html

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]